KPRX · Company research
Kiora Pharmaceuticals, Inc. Common Stock (KPRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
14records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis - kalkine.ca | Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis kalkine.ca | View source ↗ | kalkine.ca | Oct 6, 2026 | neutral | 0 | 0.6 |
| KPRX Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.34 Per Share Tops Consensus - Earnings Season Preview - dars.gov.et | KPRX Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.34 Per Share Tops Consensus - Earnings Season Preview dars.gov.et | View source ↗ | dars.gov.et | Sep 28, 2026 | neutral | 0 | 0.6 |
| KPRX Q2 2026 Earnings: Loss Narrows Past Estimates, but Shares Slide on Pre-Revenue Profile - Financial Health Score - dars.gov.et | KPRX Q2 2026 Earnings: Loss Narrows Past Estimates, but Shares Slide on Pre-Revenue Profile - Financial Health Score dars.gov.et | View source ↗ | dars.gov.et | Sep 21, 2026 | neutral | 0 | 0.6 |
| New investor crosses 5% ownership in Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan | New investor crosses 5% ownership in Kiora Pharmaceuticals (NASDAQ: KPRX) Stock Titan | View source ↗ | Stock Titan | Sep 17, 2026 | neutral | 0 | 0.6 |
| Kiora Pharmaceuticals Bolsters Leadership in Clinical Development - The Globe and Mail | Kiora Pharmaceuticals Bolsters Leadership in Clinical Development The Globe and Mail | View source ↗ | The Globe and Mail | Sep 9, 2026 | neutral | 0 | 0.6 |
| Kiora Pharmaceuticals (KPRX) Rises to $2.59, Holding Support as Biotech Traders Eye Resistance - Bull Pennant - dars.gov.et | Kiora Pharmaceuticals (KPRX) Rises to $2.59, Holding Support as Biotech Traders Eye Resistance - Bull Pennant dars.gov.et | View source ↗ | dars.gov.et | Sep 2, 2026 | neutral | 0 | 0.6 |
| Kiora Pharmaceuticals (KPRX) Rises to $2.59, Holding Support as Biotech Traders Eye Resistance - Liquidity Sweep - siam.in | Kiora Pharmaceuticals (KPRX) Rises to $2.59, Holding Support as Biotech Traders Eye Resistance - Liquidity Sweep siam.in | View source ↗ | siam.in | Sep 2, 2026 | neutral | 0 | 0.6 |
| 10,000-plus in South Korea are estimated to have a rare retinal disease; Kiora licenses KIO-301 - Stock Titan | 10,000-plus in South Korea are estimated to have a rare retinal disease; Kiora licenses KIO-301 Stock Titan | View source ↗ | Stock Titan | Aug 19, 2026 | neutral | 0 | 0.6 |
| KPRX Forecast — Price Target — Prediction for 2027 - TradingView | KPRX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits | Why Did KPRX Stock Surge 17% Pre-Market Today? Stocktwits | View source ↗ | Stocktwits | Apr 7, 2026 | neutral | 0 | 0.6 |
| KIORA PHARMACEUTICALS Earnings Results: $KPRX Reports Quarterly Earnings - Quiver Quantitative | KIORA PHARMACEUTICALS Earnings Results: $KPRX Reports Quarterly Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Nov 7, 2025 | neutral | 0 | 0.6 |
| Kiora Pharmaceuticals (KPRX) Stock Forecast and Price Target 2026 - MarketBeat | Kiora Pharmaceuticals (KPRX) Stock Forecast and Price Target 2026 MarketBeat | View source ↗ | MarketBeat | May 11, 2024 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Feb 12, 2024 | neutral | 0 | 0.6 |
| Kiora Pharmaceuticals, Inc. (KPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Kiora Pharmaceuticals, Inc. (KPRX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 27, 2022 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.